# Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

> **NCT03412630** · NA · TERMINATED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **RADIATION:** Computed Tomography Perfusion Imaging

## Key facts

- **NCT ID:** NCT03412630
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-13
- **Primary completion:** 2019-03-19
- **Final completion:** 2020-07-22
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412630, "Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03412630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*